Corrigendum to "Phase 1/2 trial of glasdegib in patients with primary or secondary myelofibrosis previously treated with ruxolitinib" [Leukemia Res. 79 (2019) 38-44]
1 Leukemia and Myeloid Disorders Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, 9500 Euclid Avenue, Cleveland, OH 44195, USA. Electronic address: gerdsa@ccf.org.
2 Tokyo Medical University, 6-1-1 Shinjuku, Shinjuku-ku, Tokyo 160-8402, Japan.
3 Weill Cornell Medical College of Cornell University, 1300 York Ave, New York, NY 10065, USA.
4 Huntsman Cancer Institute, University of Utah, 2000 Circle of Hope Dr, Salt Lake City, UT 84112, USA.
5 Moores Cancer Center, University of California, San Diego, 3855 Health Sciences Dr, La Jolla, CA 92093, USA.
6 UT Health San Antonio Cancer Center, 7979 Wurzbach Rd, San Antonio, TX 78229, USA.
7 Columbia University Medical Center, 630 West 168th St, New York, NY 10032, USA.
8 Juntendo University School of Medicine, 2-1-1, Hongo, Bunkyo-ku, Tokyo 113-8421, Japan.
9 Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital and Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan.
10 Pfizer Inc, 235 East 42nd St, New York, NY 10017, USA.
11 Pfizer Inc, 10555 Science Center Drive, San Diego, CA 92121 USA.
12 Comprehensive Cancer Center, University of Michigan, 1500 East Medical Center Dr, Ann Arbor, MI 48109, USA.